Chemung Canal Trust Co. acquired a new stake in GlaxoSmithKline PLC (NYSE:GSK) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 4,859 shares of the pharmaceutical company’s stock, valued at approximately $210,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. FMR LLC raised its position in GlaxoSmithKline PLC by 11.7% in the first quarter. FMR LLC now owns 23,635,038 shares of the pharmaceutical company’s stock valued at $996,452,000 after buying an additional 2,482,009 shares during the period. Fisher Asset Management LLC raised its position in GlaxoSmithKline PLC by 4.7% in the second quarter. Fisher Asset Management LLC now owns 12,534,385 shares of the pharmaceutical company’s stock valued at $540,483,000 after buying an additional 564,519 shares during the period. Bank of America Corp DE raised its position in GlaxoSmithKline PLC by 15.8% in the first quarter. Bank of America Corp DE now owns 6,849,632 shares of the pharmaceutical company’s stock valued at $288,780,000 after buying an additional 934,928 shares during the period. Renaissance Technologies LLC raised its position in GlaxoSmithKline PLC by 42.7% in the first quarter. Renaissance Technologies LLC now owns 4,402,100 shares of the pharmaceutical company’s stock valued at $185,593,000 after buying an additional 1,316,600 shares during the period. Finally, Brandes Investment Partners LP raised its position in GlaxoSmithKline PLC by 6.8% in the first quarter. Brandes Investment Partners LP now owns 3,363,788 shares of the pharmaceutical company’s stock valued at $141,817,000 after buying an additional 214,167 shares during the period. 8.96% of the stock is owned by hedge funds and other institutional investors.

GlaxoSmithKline PLC (NYSE GSK) traded down 0.26% during trading on Friday, reaching $42.66. The company’s stock had a trading volume of 2,280,071 shares. The company has a 50-day moving average of $43.28 and a 200 day moving average of $41.70. The firm has a market cap of $104.22 billion, a PE ratio of 47.72 and a beta of 1.04. GlaxoSmithKline PLC has a one year low of $37.20 and a one year high of $45.58.

GlaxoSmithKline PLC (NYSE:GSK) last announced its earnings results on Wednesday, April 26th. The pharmaceutical company reported $0.62 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.62. GlaxoSmithKline PLC had a net margin of 5.48% and a return on equity of 113.31%. The business had revenue of $9.23 billion during the quarter, compared to the consensus estimate of $9.09 billion. Analysts expect that GlaxoSmithKline PLC will post $2.86 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, July 13th. Shareholders of record on Friday, May 12th were paid a dividend of $0.483 per share. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date of this dividend was Wednesday, May 10th. This represents a $1.93 dividend on an annualized basis and a dividend yield of 4.53%. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is currently 233.74%.

WARNING: “Chemung Canal Trust Co. Takes Position in GlaxoSmithKline PLC (GSK)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/07/22/chemung-canal-trust-co-takes-position-in-glaxosmithkline-plc-gsk.html.

Several research analysts have recently weighed in on GSK shares. Zacks Investment Research lowered GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday. J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Friday, June 16th. ValuEngine lowered GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Berenberg Bank raised GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research report on Friday, May 26th. Finally, BNP Paribas lowered their price objective on GlaxoSmithKline PLC to $37.00 in a research report on Thursday, April 6th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and ten have issued a buy rating to the company. GlaxoSmithKline PLC currently has a consensus rating of “Hold” and an average target price of $46.00.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Stock Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related stocks with our FREE daily email newsletter.